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Abstract 
Introduction: Human nutrition plays an important role in immune function and 
protection against infectious diseases. Populations experiencing nutritional 
deficiencies may benefit less from vaccines (which require robust immune 
system function) and may be at increased risk of disease. 
Methods: I identified populations living in the African meningitis belt and 
assessed potential relationships between 1) protein-energy undernutrition and 
meningococcal vaccine immunogenicity; 2) iron and vitamin A deficiency and 
long-term vaccine antibody persistence; and 3) iron status and risk of 
asymptomatic nasopharyngeal carriage of Neisseria meningitidis (Nm). 
Results: Protein-energy undernutrition was not consistently significantly related to 
meningococcal vaccine immunogenicity in children 0-2 years old. However, 
increasing iron status was significantly related to a reduction in meningococcal 
vaccine-elicited antibody at 2 years post-vaccination. Finally, increasing iron 
status was significantly related to reduced odds of asymptomatic nasopharyngeal 
carriage of Nm in children 5-11 (for iron measured by serum ferritin) and 12-17 
(for iron measured by soluble transferrin receptor) years old. 
Discussion: This dissertation identifies potential relationships between iron status 
and meningococcal vaccine antibody persistence as well as the odds of Nm 
carriage. Further studies should assess these relationships in larger populations 
of children, at a greater number of time points, and consider additional iron 
biomarkers. 
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Introduction 
 
Meningococcal meningitis is caused by Neisseria meningitidis, a Gram-
negative bacterium (1) with 13 known serogroups, defined by differences in the 
structure of the bacterium’s polysaccharide capsule (2, 3). Of these serogroups, 
six (A, B, C, W, X and Y) cause the majority of meningococcal disease worldwide 
(3-5). The disease burden is highest in Africa, with attack rates as high as 1,000 
per 100,000 population; in other areas of the world, attack rates range from 0.3 to 
3 per 100,000 population (6). The case fatality ratio has been estimated to be 
between 10% and 20% worldwide (7); similar estimates have been reported for 
recent meningococcal meningitis outbreaks in African countries (8). Survivors 
can suffer from permanent sequelae including deafness, cognitive impairment, 
seizures, and gangrene resulting in limb amputation (1, 9, 10). Meningococcal 
meningitis disease progresses rapidly and requires intensive supportive care, 
including administration of antibiotics and lumbar punctures that may be difficult 
to provide during epidemic conditions (1, 3). In addition to invasive infection, the 
bacterium is also capable of colonizing the upper respiratory tract (11), resulting 
in asymptomatic carriage lasting days or weeks. 
Seasonal epidemics of meningococcal meningitis have been occurring for 
more than a century across the Sahel region of Africa; this area is called the 
“African meningitis belt” (12, 13). The African meningitis belt encompasses 22 
countries and more than 400 million people (12), and has a high number of 
epidemics per year and higher rates of meningococcal meningitis overall, 
	 2 
compared to Western countries (3). Local epidemics of meningococcal meningitis 
in the meningitis belt seem to be seasonal (occurring during the dry season); 
large epidemics are cyclical in nature (occurring approximately every 5-8 years) 
(6).  
Historically, outbreaks of meningococcal meningitis in the African 
meningitis belt have been reactively controlled using vaccination with 
polysaccharide vaccines (14-16), which contain antigens against bacterial 
capsular polysaccharides. However, reactive vaccination strategies are often too 
slow to control outbreaks effectively (14, 17); polysaccharide C, Y and W 
vaccines do not provide protection in children under 2 years; and the 
immunogenicity of polysaccharide A vaccines in young children is unclear (18). In 
order to better control epidemics of meningococcal meningitis, a new vaccine 
was developed against N. meningitidis serogroup A (NmA) (14). This vaccine, 
called MenAfriVac, contains NmA polysaccharide conjugated to a tetanus toxoid 
protein (19). MenAfriVac is safe (20) and efficacious (21), and provides antibody 
persistence for several years (22, 23). MenAfriVac vaccination campaigns have 
successfully reduced the incidence of meningitis caused by NmA (2, 24).  
Although MenAfriVac immunogenicity is high, some studies have noted 
heterogeneity in immunogenicity and persistence of vaccine-elicited antibody 
according to demographic and immune factors (22, 25). This may leave some 
vaccinated groups more vulnerable to post-vaccination infection with NmA. 
MenAfriVac immunogenicity may vary depending on factors including age and 
	 3 
gender (25) and pre-vaccination levels of antibody (26). Studies on other 
vaccines have indicated that infant protein-energy and micronutrient 
undernutrition may also be associated with vaccine immunogenicity, though 
experts note that study results are conflicting depending on the setting, the 
pathogen, and the nutritional markers measured (27, 28).  
Children with protein-energy undernutrition, a condition that results from a 
lack of sufficient energy and/or protein and leads to deficits in growth, are a 
population that is at increased risk of infectious disease morbidity and mortality 
(29). PEU is associated with poorer immune function and increased risk of 
infection (29, 30) in children. Infection in early childhood can impair the 
development of gut and lung epithelia, which increases the risk of future infection 
while also inhibiting the uptake of nutrients across gut epithelia (29). This 
inhibited uptake of nutrients results in further delays in epithelial development, 
further increasing the risk of infection. As a result, this interaction is termed a 
“vicious cycle” between infection and nutrition (31). Because PEU is considered 
to be an immunosuppressive state, it has been hypothesized that PEU may also 
negatively affect childhood immune response to vaccination (27, 28). Although 
this possibility has been investigated for many types of vaccines, including oral 
vaccines (27, 28), few studies have investigated this association for 
meningococcal meningitis vaccines (27). To our knowledge, no study has 
assessed the possible relationship between undernutrition and immune response 
to meningococcal conjugate vaccines (28). 
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In addition to PEU, low iron and low vitamin A are common in children in 
African meningitis belt countries (32, 33). Children with iron or vitamin A 
deficiency may be at increased risk for infection because both iron and vitamin A 
have been implicated in immune system function and child survival (29). 
Dendritic cells in the gut and lungs convert retinal (a derivative of vitamin A) to 
retinoic acid (RA, vitamin A’s active form), identifying RA as a component of the 
immune protection of barrier sites (34). RA also aids the conversion of CD4+ T 
cells to induced regulatory T cells in vitro, and the conversion of CD4+ T cells to 
CD8+ T cells within intestinal epithelia (34). Meanwhile, iron is required for the 
survival of most bacterial and viral pathogens (35) and is therefore sequestered 
by the human immune system during times of acute infection, a process termed 
“nutritional immunity” (36). Iron also plays a role in natural host immunity in the 
absence of infection: iron availability modulates the balance between populations 
of Th1 and Th2 T helper cell subsets (37, 38), and is instrumental in the creation 
of toxic oxygen and nitrogen species that can kill microbes (39). Because iron 
and vitamin A are implicated in immune system function, vaccine immunogenicity 
and long-term antibody persistence (both of which require functional immune 
responses) in young children could vary according to iron or vitamin A status. 
Finally, the probability of carriage of N. meningitidis may vary based on 
individual nutritional status. Other studies have indicated that Plasmodium 
falciparum, the parasite that causes malaria, may survive more easily in 
individuals with high iron levels (40). This observation regarding malaria and iron 
	 5 
has raised concerns about whether iron supplementation for anemic populations 
should be carried out in areas of the world with high malaria prevalence. Like P. 
falciparum, N. meningitidis requires iron to reproduce (41). So far, however, no 
studies have investigated whether iron levels are related to the risk of N. 
meningitidis infection or asymptomatic carriage. Since iron-deficiency anemia is 
also relatively common in the African meningitis belt (42), this question is of 
pressing concern. The prevalence of asymptomatic carriage of Nm is recognized 
as a predictive factor in meningococcal meningitis outbreaks (43, 44), but it has 
been noted that relatively little is known about the natural history of 
nasopharyngeal carriage of meningococcal meningitis (45, 46). A better 
understanding of the potential nutritional risk factors for Nm carriage could help 
contextualize the high variation in carriage prevalence and carriage type seen 
across the meningitis belt (45, 46).	
The next steps in the control of meningococcal meningitis are therefore 1) 
to understand heterogeneity of the immune response to vaccination according to 
nutritional status, and 2) to elucidate the possible connections between nutrition 
and N. meningitidis carriage probability. So far, no study has assessed the 
impact of undernutrition on immediate or long-term immunogenicity of 
MenAfriVac, and no study has investigated a connection between iron 
undernutrition and N. meningitidis carriage. The analyses described in this 
dissertation seek to answer these questions. 
	 6 
Understanding the heterogeneity of immune response to vaccination and 
the potential association of MenAfriVac vaccination with increases in non-NmA 
serogroup incidence has important implications for current MenAfriVac 
vaccination campaigns and the future tailoring of vaccination campaigns for non-
NmA serogroups of N. meningitidis.  
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Chapter 1: Meningococcal vaccines and protein-energy 
undernutrition in children in the African meningitis belt 
 
 
Introduction 
Meningococcal meningitis is a serious health problem in a region of Africa 
known as the African meningitis belt (12). In this area, young children experience 
a high burden of meningococcal disease (3). There are several vaccines 
available to prevent meningococcal disease and control outbreaks. These 
include PsACWY, a quadrivalent polysaccharide vaccine against Neisseria 
meningitidis serogroups A, C, W and Y; and PsA-TT, a polysaccharide-protein 
conjugate vaccine against N. meningitidis serogroup A. PsACWY is routinely 
used for outbreak control (2) and PsA-TT mass-vaccination campaigns have 
significantly reduced the burden of MenA disease in Africa since their 
introduction in 2010 (16). The World Health Organization recently issued a 
recommendation to incorporate PsA-TT into standard infant immunization 
schedules (47). Adding PsA-TT to infant immunization schedules means that all 
children, including vulnerable populations at increased risk of infection, will be 
eligible for vaccination.  
Children with protein-energy undernutrition, a condition that results from a 
lack of sufficient energy and/or protein and leads to deficits in growth, are at 
increased risk of infectious disease morbidity and mortality (29). Protein-energy 
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undernutrition (PEU) can range from mild to severe and is diagnosed by 
comparing child-specific anthropometric values to corresponding WHO growth 
standards. PEU is prevalent in the countries of the African meningitis belt. Of 
children under 5 in urban Mali, approximately 21% have a weight-for-age value 
more than 2 standard deviations below the WHO reference mean, and 28% have 
a height-for-age value more than 2 standard deviations below the WHO 
reference mean (48). Similar estimates are seen in children under 5 in other 
meningitis belt countries, including Senegal (49), the Gambia (50), and Ghana 
(51). PEU is of special concern in areas with relatively higher risk of infectious 
disease such as the meningitis belt, because PEU is associated with poorer 
immune function and increased risk of infection (29, 30) in children. Infection in 
early childhood can impair the development of gut and lung epithelia, which 
increases the risk of future infection while also inhibiting the uptake of nutrients 
across gut epithelia (29). This inhibited uptake of nutrients results in further 
delays in epithelial development, further increasing the risk of infection. As a 
result, this interaction is termed a “vicious cycle” between infection and nutrition 
(31). Because PEU is considered to be an immunosuppressive state, it has been 
hypothesized that PEU may also negatively affect childhood immune response to 
vaccination (27, 28). Although this possibility has been investigated for many 
types of vaccines, including oral vaccines (27, 28), few studies have investigated 
this association for meningococcal meningitis vaccines (27). The few existing 
studies on this topic present conflicting findings, study only a short time-scale 
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post-vaccination (most studies measured post-vaccination antibody at 2 or 4 
weeks post-vaccination only), and were largely conducted several decades ago 
with different vaccines than are currently used (52-55). Given the high 
prevalence of PEU in children living in the meningitis belt and the potential for 
PEU to limit immunological protection against infectious diseases, additional 
research is needed to investigate anthropometric growth indices and vaccine 
antibody response in the context of current meningococcal meningitis vaccines 
and to examine vaccine-elicited antibody on a longer time scale.  
 We investigated whether anthropometric growth indices in children living 
in the meningitis belt were associated with reduced meningococcal meningitis 
vaccine antibody response and long-term antibody persistence. We analyzed the 
relationship between growth indices and two different meningococcal vaccines. 
First, we investigated PsA-TT, a polysaccharide-protein conjugate vaccine. This 
vaccine is capable of eliciting a more robust immune response than 
polysaccharide-only vaccine because the conjugated protein is able to elicit a T 
cell-dependent response which primes immunological memory (14, 56), whereas 
polysaccharide-only vaccine antigens are only able to elicit a B cell immune 
response (19). Second, we investigated PsACWY, a quadrivalent polysaccharide 
vaccine that elicits an immune response using only polysaccharide. We analyzed 
vaccine antibody response and long-term antibody persistence according to 
conventional childhood growth indices (height-for-age, weight-for-height, and 
weight-for-age). 
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Materials and methods 
Participants and data collection 
This is a secondary analysis based on data from three clinical trials 
conducted as part of the Meningitis Vaccine Project. These trials were originally 
designed to quantify the safety and immunogenicity of PsA-TT in African children 
(57, 58). Our analysis uses clinical trial data from Malian children 12-23 months 
old (PsA-TT-002, conducted 2006-2008); Ghanaian children 14-18 weeks old 
(PsA-TT-004, conducted 2008-2011); and Malian children 9-12 months old (PsA-
TT-007, conducted 2012-2013). A direct comparison of these studies can be 
found in Table 1. PsA-TT-002 randomized participants to receive PsA-TT, 
PsACWY, or a Haemophilus influenzae type b (Hib) conjugate vaccine in a 1:1:1 
ratio (our analysis does not include children who received the Hib conjugate 
vaccine). In PsA-TT-004 and PsA-TT-007, all participants received PsA-TT 
(Table 1).  
In each of these studies, participants provided blood samples and 
demographic information at pre-vaccination and 28-35 days post-vaccination.  
Additional blood samples and demographic information were provided at 10 
months post-vaccination in PsA-TT-002, at 5 months post-vaccination in PsA-TT-
004, and at 6 months post-vaccination in PsA-TT-007 (Table 1). Children were 
eligible for the original clinical trials if they were “free of obvious health problems”, 
per the child’s medical history and judgment of the trial investigator (57, 58). 
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Protocols from PsA-TT-002 and PsA-TT-003 are available online (57) and results 
of the primary trial aims have been published previously for PsA-TT-002 (57). 
 
Laboratory methods and anthropometric measurement techniques 
The methods to analyze serum samples collected from these three studies 
have been described elsewhere in detail (57, 58). Briefly, PsA-TT and PsACWY 
immunogenicity generated against N. meningitidis serogroup A was assessed 
just before vaccination and at several time points after vaccination, using group A 
serum bactericidal antibody with rabbit complement (rSBA). The rSBA reference 
strain was F8238; titers were expressed as the reciprocal of the final serum 
dilution. The lower limit of detection in PsA-TT-002 was an rSBA value of 4 (the 
LLQ has not yet been published for PsA-TT-004 and PsA-TT-007); samples with 
rSBA < 4 were assigned a value of 2 (57). Participant pre-vaccination weight, 
height (PsA-TT-002), length (PsA-TT-004 and PsA-TT-007), sex, and age, all 
collected after enrollment in the trials. We calculated weight-for-age (WAZ), 
weight-for-height (WHZ), and height-for-age (HAZ) Z-scores by comparing each 
child’s measurements to the WHO 2006 Growth Standards (59). We compared 
children with the following Z-score categories: < -2 (the reference category); ≥ -2 
and < -0; and ≥ 0.  
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Statistical analysis 
Because rSBA antibody titers are results of a serial twofold dilution assay, 
rSBA values were log2-transformed. We used generalized linear regression 
analyses to investigate whether the change in antibody from pre-vaccination to 
28-35 days post-vaccination was associated with categories of HAZ, WHZ, or 
WAZ. To account for potentially confounding differences between studies, we 
controlled for both the specific study and the country in which the study took 
place (a compound variable we called “study location”). 
 We then used mixed linear regressions with random intercepts and 
random slopes to investigate whether post-vaccination antibody levels, and the 
rate of decline in antibody over the year post-vaccination, differed according to 
categories of HAZ, WHZ, or WAZ. In order to identify a potential association 
between anthropometric Z-score categories and the rate of decline in antibody 
over time, we incorporated interaction terms between Z-score categories and 
time since vaccination (in months) in the random-effects models. For these 
analyses, we assumed an exponential decline in antibody, meaning that we 
modeled a linear decline in log-transformed antibody. We excluded information 
about pre-vaccination antibody titer to model this linear decline. Children who 
received PsA-TT had antibody titer measured during at least 2 of the following 
time points: 1, 5, 6, and 10 months post-vaccination. Children who received 
PsACWY had antibody titer measured during at least 2 of the following time 
points: 1, 6, and 10 months post-vaccination (Table 1). Finally, in order to 
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provide additional context for results presented as log2 rSBA, the predicted mean 
rSBA was calculated for each month post-vaccination, using the Stata -margins- 
command.  
 
Results 
A total of 620 children were included in our analysis, including 199 
(28.9%) from PsA-TT-002, 142 (20.6%) from PsA-TT-004, and 279 (40.6%) from 
PsA-TT-007 (Table 1). Of these participants, 310 (50.0%) were female; the mean 
(SD) age was 0.86 (0.45) years, and 521 (84.0%) received PsA-TT (Table 2). 
Pre-vaccination rSBA levels were low and increased immediately following 
vaccination in both PsA-TT and PsACWY recipients (Table 2, Figure 1), as has 
been reported previously (57). 
 In adjusted linear regression models, there was no evidence that HAZ 
(Table 3), WAZ (Table 4), or WHZ (Table 5) were associated with the change in 
PsA-TT-elicited antibody from pre-vaccination to 28-35 days post-vaccination. No 
association was identified between any anthropometric growth indices and the 
change in PsA-TT-elicited antibody from pre- to 28-35 days post-vaccination 
(Tables 3-5). In PsACWY recipients, WHZ ≥ -2 and < 0 (compared to WHZ < -2) 
was associated with an increase in log2 rSBA (difference: 2.45, 95% CI: 0.28 – 
4.62) (Table 4), though this was not seen for other growth indices. 
In adjusted mixed linear regression models with random intercepts and 
random slopes, increasing time post-vaccination was associated with a decline in 
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rSBA for both PsA-TT and PsACWY recipients, as expected (Tables 3-5). 
Nevertheless, interaction terms between HAZ, WHZ or WAZ and time post-
vaccination (in months) were not found to be associated with rSBA in PsA-TT or 
PsACWY recipients (Tables 3-5, Figure 2). In these models, there was an 
association between WHZ ≥ -2 and < 0 (compared to WHZ < -2) and increased 
PsA-TT elicited antibody (difference in log2 rSBA: -1.03, 95% CI: -1.94, -0.12) 
(Table 4), and an association between WAZ ≥ -2 and < 0 (compared to WHZ < -
2) (difference in log2 rSBA: 1.04, 95% CI: 0.07, 2.01) (Table 5). These results 
were not seen for PsACWY recipients.  
The predicted mean rSBA for each anthropometric growth index was 
similar among PsA-TT recipients (rSBA range at 1 month post-vaccination: 
1789.1 – 3224.8; rSBA range at 12 months post-vaccination: 62.1 – 412.4), and 
did not vary by growth index (Figure 2). The predicted mean rSBA for each 
anthropometric growth index was similar among PsACWY recipients (average 
rSBA at 1 month post-vaccination: 80.9 – 270.6; average rSBA at 12 months 
post-vaccination: 24.7 – 143.6), and did not vary by growth index (Figure 2). 
 
Discussion 
This analysis did not identify an association between HAZ, WHZ, or WAZ 
and the difference in rSBA antibody from pre- to 28-35 days post-vaccination with 
PsA-TT, but did identify an association between increasing WHZ and increasing 
rSBA from pre- to 28-35 days post-vaccination with PsACWY. Our analysis did 
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not identify an association between HAZ and PsA-TT antibody in a longitudinal 
analysis in the year following vaccination. Our analysis identified a potential 
association between lower WHZ and higher PsACWY-elicited antibody, and 
higher WAZ and higher PsACWY-elicited antibody, in a similar longitudinal 
analysis using random effects models. In these longitudinal analyses, neither 
PsA-TT recipients nor PsACWY recipients’ post-vaccination antibody levels were 
significantly related to interaction terms between WAZ and time since 
vaccination. Results from this analysis do not consistently support the hypothesis 
that lower anthropometric growth indices are related to reduced PsA-TT or 
PsACWY antibody response, or lower antibody persistence, in children living in 
the African meningitis belt.  
 Our findings are similar to two previous studies conducted in Nigeria on 
the immune response to meningococcal polysaccharide vaccine published in the 
1980s. In one study, the antibody response to group C meningococcal 
polysaccharide vaccine did not differ according to different deciles of weight-for-
age, height-for-age, and arm circumference-for-age measures (although children 
with severe, “obvious” clinical malnutrition were excluded from the study) (54); in 
the other, the antibody response to several vaccines (including group A and 
group C meningococcal vaccine) did not differ according to weight-for-age 
measurements standard at the time (55). Our findings differ from another 1980s 
study on the immunological response to meningococcal polysaccharide vaccine 
among well-nourished and undernourished children in Nigeria, which found 
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reduced meningococcal A and meningococcal C-specific IgM, IgG and IgA 
responses to meningococcal polysaccharide vaccine in undernourished children 
(53). However, that study included a relatively small number of undernourished 
children (n = 14), the definition of undernourishment was not described, and the 
study was published 28 years before the introduction of PsA-TT in the African 
meningitis belt in 2010, during a time when standard analytic methods for 
nutrition and immunogenicity differed from current protocols. Furthermore, it is 
difficult to draw direct comparisons between immunoglobulin titer (reported in the 
study mentioned) and rSBA titers (reported in our analysis). 
 Among several comparisons, our analysis identified one statistically 
significant relationship between WAZ ≥ -2 and < 0, and increased rSBA during a 
year after vaccination with PsACWY. This result should be interpreted with 
caution for the following reasons: it was not replicated in analyses with PsA-TT, 
or with any other anthropometric value; the confidence interval for the statistically 
significant estimate was broad and the upper bound neared 1 (95% CI: 1.02 – 
3.40); and an interaction term between WAZ and time since vaccination was not 
significantly related to vaccine antibody. In order to conclusively identify a 
relationship between increasing WAZ and decreasing antibody from PsACWY, 
additional studies specifically designed to investigate this question are 
necessary. 
This study has several limitations. First, because this analysis 
incorporates information on vaccine antibody response and anthropometrics from 
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four clinical trials which took place in three different countries, and because the 
age of eligible participants differed slightly by study, there was random variation 
in participant anthropometrics and baseline antibody level by study and country. 
Despite the potential for unmeasured confounding, inclusion and exclusion 
criteria were otherwise similar between studies (57, 58), and all followed similar 
protocols. Additionally, we have accounted for potential between-study variation 
by including a regression covariate to describe study and country.  
 Second, children were excluded from the original clinical trials if they had 
“obvious health problems” (53). Therefore, although nutritional status was not a 
direct component of the study inclusion or exclusion criteria, this criterion may 
have resulted in the exclusion of some children with undernutrition. Recent 
estimates of HAZ < -2 in children 0-5 years old across Mali, Senegal, Ghana, and 
The Gambia are between 15.5% and 38% (48-51); estimates of WHZ < -2 are 
between 13% (49) and 17% (60), and estimates of WAZ < -2 are between 6.2% 
(60) and 26% (50). However, the prevalences of WHZ <-2 and WAZ <-2 in this 
analysis are similar to prevalence estimates reported for the general population, 
but the prevalence of HAZ <-2 in this analysis is slightly lower than reported for 
the overall population.  
 Finally, the longitudinal component of this analysis made use of several 
time points post-vaccination. However, these time points were not shared by all 
studies that comprised the analysis; the models used assume exponential decay 
of antibody over time; and post-vaccination time points were only included up to 
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10 months after vaccination. Future analyses would benefit from including 
additional time points post-vaccination and for a longer period of time (for 
example, at each month post-vaccination for several years), for higher analytic 
granularity. 
 
Conclusion 
This analysis did not identify a consistent relationship between protein-
energy undernutrition and reduced vaccine antibody response or antibody 
persistence of PsA-TT or PsACWY in children living in the African meningitis belt. 
Future studies should consider measuring antibody titers at additional time points 
post-vaccination, and for longer periods of time, to determine if the rate of 
antibody waning over a period of several years is associated with nutritional 
status.  
 
Acknowledgments 
The authors gratefully acknowledge the work of the trial coordinators and 
field workers, the laboratory technician staff at Public Health England and 
NutriSurvey, and the contributions of the study participants themselves. The 
authors are additionally grateful for the scientific input and expertise of Dr. Ellen 
Demerath, PhD. 
  
	 19 
Table 1. Number of participants and timing of post-vaccination blood sample 
collection, by study. 
Study 
name 
Country Partici-
pants 
(N) 
Partici-
pant 
ages 
Years 
of 
study 
Study 
vaccines 
Post-
vaccination 
timepoints  
PsA-
TT-
002 
Mali 199 12-23 
months 
old 
2006-
2008 
PsA-TT, 
PsACWY, 
and Hib 
conjugate 
vaccinea 
(random-
ized in 
1:1:1 
ratio) 
• 1 month 
• 10 
months 
PsA-
TT-
004 
Ghana 142 14-18 
weeks 
old 
2008-
2011 
PsA-TT 
only 
• 1 month 
• 5 months 
PsA-
TT-
007 
Mali 279 9-12 
months 
old 
2012-
2013 
PsA-TT 
only 
• 1 month 
• 6 months 
a Only children who received PsA-TT or PsACWY were included in this analysis.  
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Table 2. Demographic and anthropometric characteristics of study participants. 
Characteristic PsA-TT recipients  
(N = 521) 
PsACWY 
recipients  
(N = 99) 
Age: mean (SD) 0.75 (0.39 1.42 (0.30) 
Female sex: N (%) 265 (50.9) 45 (45.5) 
Study and study site: N (%)   
PsA-TT-002, Mali 100 (19.2) 99 (100) 
PsA-TT-004, Ghana 142 (27.3) 0 (0) 
PsA-TT-007, Mali 279 (53.6) 0 (0) 
rSBA GMT (95% CI)   
Pre-vaccination 2.8 (2.5 – 3.2) 4.5 (3.0 – 6.8) 
28-35 days post-vaccination  3297.4 (2822.3 – 
3852.7) 
200.4 (112.1 – 
358.2) 
Anthropometric measurementsa   
HAZ categories: N (%)   
Z-score <-2 20 (3.8) 16 (16.2) 
Z-score ≥ -2 and < 0 274 (52.6) 51 (51.5) 
Z-score ≥ 0 227 (43.6) 32 (32.3) 
WHZ categories: N (%)   
Z-score < -2 67 (12.9) 20 (20.2) 
Z-score ≥ -2 and < 0 308 (59.1) 62 (62.6) 
Z-score ≥ 1 146 (28.0) 17 (17.2) 
WAZ categories: N (%)   
Z-score < -2 44 (8.5) 18 (18.2) 
Z-score ≥ -2 and < 0 338 (64.9) 65 (65.7) 
Z-score ≥ 0 139 (26.7) 16 (16.2) 
HAZ: mean (SD) -0.19 (1.11) -0.90 (1.26) 
WHZ: mean (SD) -0.63 (1.17) -1.00 (1.33) 
WAZ: mean (SD) -0.56 (1.04) -1.01 (1.16) 
a Anthropometric measurements are measured in Z-scores. A Z-score of 0 
indicates that the value for an individual is equal to the reference value mean; a 
Z-score less than 0 indicates that the value for an individual is lower than the 
reference value mean. 
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Table 3. The difference in rSBA from pre- to post-vaccination with PsA-TT and 
PsACWY, and the relationship between height-for-age and decline in antibody 
over time. a 
Characteristic PsA-TT PsACWY 
 rSBA 
difference 
95% CI rSBA 
difference 
95% CI 
Model 1: Antibody 
difference from pre- to 
28-35d post-
vaccination 
      
Z-score < -2 (ref) -- -- -- -- -- -- 
Z-score ≥ -2 and < 0 0.16 -1.21 1.52 0.14 -2.36 2.63 
Z-score ≥ 0 0.42 -0.97 1.80 0.36 -2.43 3.16 
       
Model 2: Antibody 
decline over time post-
vaccinationb 
      
Z-score < -2 (ref) -- -- -- -- -- -- 
Z-score ≥ -2 and < 0 -0.37 -1.77 1.03 0.17 -1.87 2.20 
Z-score ≥ 0 0.06 -1.35 1.47 1.00 -1.26 3.26 
Time since 
vaccination (in 
months) -0.50 -0.74 
-
0.26 -0.12 -0.34 0.09 
Time*Z-score < -2 -- -- -- -- -- -- 
Time*Z-score ≥ -2 
and < 0 0.23 -0.02 0.48 -0.01 -0.26 0.24 
Time*Z-score ≥ 0 0.12 -0.14 0.37 0.03 -0.24 0.29 
a Each model shown is a separate regression model accounting for participant 
age, sex, study and study site as potential confounders. A value of 1.2 indicates 
a 20% increase in rSBA compared to the reference category or with a 1-unit 
change in the covariate of interest; a value of 0.8 indicates a 20% decrease in 
rSBA. 
b Model 2 is a mixed-effects regression with random intercept and random slope, 
assuming an exchangeable correlation matrix. 
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Table 4. Linear regressions on the change in rSBA from pre- to post-vaccination 
with PsA-TT and PsACWY, according to weight-for-height, and the relationship 
between weight-for-height and decline in antibody over time. a 
Characteristic PsA-TT PsACWY 
 rSBA 
difference 
95% CI rSBA 
difference 
95% CI 
Model 1: Antibody 
difference from pre- to 
28-35d post-
vaccination 
      
Z-score < -2 (ref) -- -- -- -- -- -- 
Z-score ≥ -2 and < 0 -0.59 -1.40 0.23 2.45 0.28 4.62 
Z-score ≥ 0 -0.76 -1.67 0.14 1.97 -0.88 4.82 
       
Model 2: Antibody 
decline over time post-
vaccination 
      
Z-score < -2 (ref) -- -- -- -- -- -- 
Z-score ≥ -2 and < 0 -0.51 -1.33 0.31 1.11 -0.77 2.99 
Z-score ≥ 0 
-1.03 -1.94 
-
0.12 -0.16 -2.52 2.21 
Time since 
vaccination (in 
months) -0.31 -0.44 
-
0.18 -0.13 -0.33 0.07 
Time*Z-score < -2 -- -- -- -- -- -- 
Time*Z-score ≥ -2 
and < 0 -0.05 -0.19 0.10 0.01 -0.22 0.24 
Time*Z-score ≥ 0 0.03 -0.13 0.20 0.02 -0.26 0.31 
a Each line shown is a separate regression model accounting for participant age, 
sex, study and study site as potential confounders. Positive values indicate an 
increase in antibody from pre- to post-vaccination associated with the 
anthropometric value. 
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Table 5. Linear regressions on the change in rSBA from pre- to post-vaccination 
with PsA-TT and PsACWY, according to weight-for-age, and the relationship 
between weight-for-age and decline in antibody over time. a 
Characteristic PsA-TT PsACWY 
 rSBA 
difference 
95% CI rSBA 
difference 
95% 
CI 
Model 1: Antibody from 
pre- to 28-35d post-
vaccination 
      
Z-score < -2 (ref) -- -- -- -- -- -- 
Z-score ≥ -2 and < 0 
0.66 -0.31 1.62 2.23 
-
0.08 4.55 
Z-score ≥ 0 
0.36 -0.69 1.42 2.78 
-
0.32 5.87 
       
Model 2: Antibody 
decline over time post-
vaccination 
      
Z-score < -2 (ref) -- -- -- -- -- -- 
Z-score ≥ -2 and < 0 
1.04 0.07 2.01 0.44 
-
1.65 2.53 
Z-score ≥ 0 
0.54 -0.52 1.60 0.35 
-
2.41 3.10 
Time since 
vaccination (in 
months) -0.19 -0.34 
-
0.04 -0.15 
-
0.38 0.07 
Time*Z-score < -2 -- -- -- -- -- -- 
Time*Z-score ≥ -2 and 
< 0 -0.16 -0.32 0.00 0.06 
-
0.19 0.31 
Time*Z-score ≥ 0 
-0.14 -0.33 0.05 -0.06 
-
0.38 0.27 
 
a Each line shown is a separate regression model accounting for participant age, 
sex, study and study site as potential confounders. Positive values indicate an 
increase in antibody from pre- to post-vaccination associated with the 
anthropometric value. 
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Figure 1. RCD curves of rSBA titers according to anthropometric growth indices 
and vaccine received.  
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Figure 2. Predicted means of rSBA for PsA-TT and PsACWY recipients, over a 
year post-vaccination. 
 
  
	 26 
 
Chapter 2: Meningococcal vaccine antibody persistence and the 
relationship to iron and vitamin A 
 
 
Introduction 
Meningococcal meningitis caused by the bacterium Neisseria meningitidis 
has historically been a serious public health problem in the African meningitis belt 
(7, 12), especially in young children (3). MenAfriVac, a polysaccharide-protein 
conjugate vaccine to prevent meningococcal disease (including meningitis) 
caused by N. meningitidis serogroup A (NmA), is safe (20) and effective (21), 
and has successfully reduced the burden of meningococcal A meningitis in Africa 
(16). After several large-scale vaccination campaigns, the World Health 
Organization has now issued a recommendation to incorporate MenAfriVac into 
standard infant immunization schedules and administer the vaccine at 9-18 
months of age (47). Clinical trials have demonstrated that MenAfriVac is highly 
immunogenic in healthy infants (57), but adding MenAfriVac to infant 
immunization schedules means that all children, including vulnerable populations 
at increased risk of infection, will be eligible for vaccination.  
One of these potentially vulnerable populations is children with low levels 
of essential vitamins and minerals such as iron and vitamin A. Low iron and low 
vitamin A are common in children in African meningitis belt countries (32, 33); in 
Mali alone, it is estimated that 61% of children under 5 experience moderate or 
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severe iron-deficiency anemia (61) and greater than 90% of children are deficient 
in vitamin A (62). Children with iron or vitamin A deficiency may be at increased 
risk for infection because both iron and vitamin A have been implicated in 
immune system function and child survival (29). In a landmark cluster-
randomized trial of vitamin A supplementation in 1986, vitamin A deficiency was 
associated with child mortality (63). More recently, in a recent systematic review 
and meta-analysis, vitamin A supplementation was found to be associated with 
reductions in childhood morbidity and mortality from diarrhea and measles (64); 
and in a randomized controlled trial in Indonesia, supplementation of vitamin A in 
both vitamin A-sufficient and vitamin A-deficient children was associated with 
increased immunogenicity for tetanus toxoid vaccine (65). Similarly, low iron 
status was associated with reduced antibody titers for tetanus toxoid vaccine and 
respiratory syncytial virus vaccine in a national cross-sectional study on nutrition 
and health in Ecuador (66). Conversely, however, supplementation of iron has 
been associated with increased risk of malaria (67), tuberculosis (68), and other 
infections (69), and iron deficiency appears to be protective against malarial 
infection in malaria-endemic areas (70). 
These proposed relationships between immune function and iron or 
vitamin A are supported by identified biological mechanisms. Dendritic cells in 
the gut and lungs convert retinal (a derivative of vitamin A) to retinoic acid (RA, 
vitamin A’s active form), identifying RA as a component of the immune protection 
of barrier sites (34). RA also aids the conversion of CD4+ T cells to induced 
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regulatory T cells in vitro, and the conversion of CD4+ T cells to CD8+ T cells 
within intestinal epithelia (34). Meanwhile, iron is required for the survival of most 
bacterial and viral pathogens (35) and is therefore sequestered by the human 
immune system during times of acute infection (36). Iron also plays a role in 
natural host immunity: iron availability modulates the balance between 
populations of Th1 and Th2 T helper cell subsets (37, 38), and is instrumental in 
the creation of toxic oxygen and nitrogen species that can kill microbes (39). 
 Because iron and vitamin A are implicated in immune system function, 
vaccine immunogenicity and long-term antibody persistence (both of which 
require functional immune responses) in young children could vary according to 
iron or vitamin A status. Given the potentially complex relationships between iron 
and vitamin A and immune system function, and the population-level deficiency 
in iron or vitamin A in the African meningitis belt, a better understanding of the 
potential associations between iron or vitamin A status and the immune response 
to meningococcal protein-conjugated polysaccharide vaccines (such as 
MenAfriVac) is needed. Therefore, we analyzed whether serum biomarkers of 
iron or vitamin A were associated with the long-term persistence of anti-MenA 
antibody in children in the meningitis belt.  Specifically, we investigated whether 
iron or vitamin A status is associated with persistence of anti-MenA antibody at 2 
years post-vaccination with MenAfriVac, and whether iron or vitamin A status is 
associated with change in anti-MenA antibody levels from 2 to 3.5 years post-
vaccination. 
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Methods 
Study population and enrollment 
From December 12, 2010 to January 11, 2011, a MenAfriVac vaccination 
campaign was administered in Bamako, Mali, to individuals 1-29 years of age 
(71). The campaign was estimated to have covered more than 99% of eligible 
individuals living in the Banconi district of Bamako (72). Two years later in 
December 2012 – January 2013, in a study led by investigators now at the 
University of Minnesota in collaboration with researchers at the Center for 
Vaccine Development-Mali, individuals living in Banconi who had been eligible 
for vaccination during the campaign were recruited for a longitudinal cohort study 
to assess the persistence of MenAfriVac-elicited antibody (the MenAfriVac 
Antibody Persistence, or MAP, Study) (22). The methods of this study have been 
described previously (22); briefly, individuals were selected in December 2012 
from an existing demographic surveillance system using a household-based, 
age-stratified random sampling design. Participants were eligible if the 
demographic surveillance system indicated they had been 1-29 years old and 
had been living in Banconi at the time of the vaccination campaign, had not 
participated in a MenAfriVac clinical trial, and had no acute or chronic health 
conditions. Study enrollees were re-contacted for a follow-up visit in May 2014. 
At both visits, participants provided demographic information and a blood 
sample. We restricted this analysis to individuals aged 1-5 years on December 1, 
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2010 at the time of vaccination, meaning individuals were 3-8 years old at the 
time of the first cohort visit in December 2012 – January 2013, and 4-9 years old 
at the time of the second cohort visit in May 2014.  
 
Laboratory methods 
The procedures for processing blood samples to extract the serum and 
quantify these markers of immunity have been described previously (22). Briefly, 
up to 8.5mL of blood was collected from each individual; the serum was 
extracted from the blood, divided into aliquots, and stored at -80°C before 
shipment to the Vaccine Evaluation Unit at Public Health England (Manchester, 
UK). The sera were assessed to quantify the complement-mediated serum 
bactericidal antibody titers, using baby rabbit complement (rSBA). The NmA 
reference strain used was F8238 (A:P1.20,9) (73). Serum samples were also 
tested for serum ferritin, soluble transferrin receptor (sTfR), retinol binding protein 
(RBP), and C-reactive protein (CRP) using a multiplex sandwich ELISA with 
HRP-coupled antibodies at the NutriSurvey lab (Wilstätt, Germany) (74).  
In this analysis, serum ferritin and sTfR were used to assess iron status 
according to WHO guidelines (75). Serum ferritin is an acute phase protein, 
meaning its blood concentrations increase during acute infection, regardless of 
dietary iron status. In the absence of infection, levels of ferritin in the blood 
correlate with liver iron stores. sTfR levels are less affected by acute infection 
(75) and reflect availability of iron in the bone marrow. Higher blood 
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concentrations of sTfR reflect poorer iron status. CRP and AGP are acute phase 
proteins that mark acute and convalescent stages of infection, respectively. 
 
Statistical analysis 
Our primary aims were to assess 1) whether iron or vitamin A status at 2 
years post-vaccination is associated with persistence of antibody at 2 years post-
vaccination, and 2) whether iron or vitamin A status at 2 years post-vaccination is 
associated with change in antibody from 2 to 3.5 years post-vaccination.  
In descriptive analyses, we defined iron deficiency as < 12µg/L for children 
< 5 years old, < 15 µg/L for children ≥ 5 years old, and < 30µg/L for children of 
any age who had CRP > 5mg/L (76). We defined RBP deficiency as < 
0.75µmol/L, abnormal sTfR as > 8.3mg/L, high CRP as > 5mg/L, and high AGP 
as > 1mg/L, per assay guidelines (74). In regression models, serum ferritin, sTfR, 
and RBP were analyzed continuously; we log10 transformed ferritin and sTfR 
because the underlying distributions of both were right-skewed. rSBA was log2 
transformed because it is a twofold serial dilution assay.  
To address our primary aims, we fit separate linear regression models to 
assess the relationship between rSBA values and serum ferritin, sTfR, or RBP 
levels.  Regression models controlled for age and sex as potential confounders, 
and included CRP and AGP as markers of concurrent acute or convalescent 
infection. Models also included information on child anthropometric growth as a 
potential confounder. Poor anthropometric growth can co-occur with deficiency in 
	 32 
iron or vitamin A (77, 78) and may have a separate potential effect on immune 
system function (79). We used participant weight, length/height, sex, and age to 
calculate weight-for-age (WAZ) and height-for-age (HAZ) Z-scores, using WHO 
child growth reference values (59). One child with a calculated HAZ > 5 standard 
deviations from the mean was excluded from the analysis, as it is likely this 
calculated value was a result of measurement error.  
 After obtaining regression coefficients for log-transformed values (log2 
rSBA), coefficients were back-transformed (2b) to obtain fold changes for raw 
antibody values (keeping in mind that a difference in log2 values translates to a 
ratio in raw values). To aid in interpretation of model results, the marginal means 
of raw rSBA were also calculated for continuous values and quintiles of serum 
ferritin, sTfR, and RBP, after controlling for confounders, using the -margins- 
command in Stata. Additionally, the same predicted marginal means of raw rSBA 
were graphed according to continuous values of serum ferritin, sTfR, and RBP. 
All analyses were performed using Stata 14 and Stata 15 (College Station, TX). 
 
Results 
There were 201 individuals who were enrolled in December 2012 – 
January 2013, approximately two years after the December 2010 MenAfriVac 
vaccination campaign. After excluding 1 individual with an unrealistic HAZ, the 
total analytic sample was 200. Of these individuals, 165 (82.5%) were 
successfully followed to 3.5 years post-vaccination. All individuals in this analysis 
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reported having received MenAfriVac during the 2010 campaign and were 1-5 
years old at the time of vaccination; none reported ever having meningitis.  
Of the 200 participants, 103 (51.5%) were female, and the mean (SD) age 
at 2 years post-vaccination was 6.0 (1.3) years. Demographic characteristics 
were similar between the participants enrolled at 2 years post-vaccination and 
the subset of the participants who were successfully followed to 3.5 years post-
vaccination (Table 6). Most individuals had serum ferritin, sTfR, and vitamin A 
values within healthy ranges, though 30% of individuals had low sTfR at 2 years 
post-vaccination (Table 6). MenA rSBA geometric mean titer (GMT) was 2870.9 
(95% CI: 2517.2 – 3274.4) at 2 years post-vaccination and significantly declined 
to 1686.1 (95% CI: 1416.0 – 2007.8) at 3.5 years post-vaccination.  
 In linear regression analyses on participants at 2 years post-vaccination, 
there was a 60% reduction in rSBA (95% CI: 19% - 80% decrease) for each unit 
increase in log10 serum ferritin (Table 7). Associations between log10 sTfR or 
RBP and rSBA were not identified at 2 years post-vaccination (Table 7). Log10 
ferritin, log10 sTfR and RBP were not found to be associated with the change in 
rSBA from 2 to 3.5 years post-vaccination (Table 8). 
 Calculated marginal means of raw rSBA at quintiles of raw serum ferritin 
reflected the association between log serum ferritin and rSBA identified in linear 
regression analyses: higher marginal mean rSBA values were seen for lower 
quintiles of serum ferritin (Table 9, Figures 7-9). As in linear regression 
analyses, marginal means of raw rSBA were not subject to substantial change 
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among quintiles of sTfR or RBP (Table 9). Similarly, marginal means of the fold 
change in rSBA from 2 to 3.5 years post-vaccination did not appear to change 
among quintiles of serum ferritin, sTfR, or RBP (Table 10, Figures 10-12). 
 
Discussion 
Our analysis identified an association between increasing log ferritin and 
decreasing rSBA at 2 years post-vaccination, supported further by an analysis 
which calculated marginal means of rSBA at 2 years post-vaccination according 
to serum ferritin quintiles. Our analysis did not identify associations between log 
ferritin, log sTfR, and RBP and the change in rSBA from 2 to 3.5 years post-
vaccination with MenAfriVac.  
 Previous studies on diphtheria and tetanus vaccine in India (80) and 
Ecuador (66), and a study on 23-valent pneumococcal vaccine in Gambian 
children (81), identified no consistent association between vitamin A deficiency 
and antibody response to vaccines. However, a randomized controlled trial in 
Indonesia identified higher IgG responses to diphtheria-tetanus-pertussis vaccine 
in children who received vitamin A supplementation, compared to those who did 
not (65). Our analysis did not identify a relationship between retinol binding 
protein and either rSBA or IgG ELISA response to MenAfriVac; however, our 
study measured vitamin A using retinol binding protein (the Indonesian study 
stated that “plasma vitamin A”, assumed to be retinol, was measured). 
Furthermore, we measured antibody outcomes 2 and 3.5 years after vaccination 
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(the Indonesian study measured antibody outcomes three weeks after 
vaccination). 
A previous study indicated that Ecuadorian children with iron deficiency 
may have lower antibody titers to diphtheria and tetanus after vaccination (66). It 
has been noted that further studies on this topic are sparse (27). Our analysis 
adds to the existing literature by describing the relationship between vaccine 
antibody and iron and vitamin A in a population-representative sample of 
otherwise healthy children rather than focusing specifically on children with iron 
or vitamin A deficiency.  
 Our analysis identified a decline in rSBA antibody titer from 2 to 3.5 years 
post-vaccination. However, at 3.5 years post-vaccination, rSBA antibody titers 
were still high, and the change in rSBA antibody titer from 2 to 3.5 years was not 
related to iron or vitamin A. Future studies assessing factors associated with the 
magnitude of post-vaccination anti-MenA antibody should consider accounting 
for potential rSBA decline over time. 
 Our analysis included CRP and AGP to account for changes in serum 
ferritin that may occur during times of acute or chronic infection and inflammation 
(75). Although the timing and magnitude of serum ferritin changes during 
infection most closely resemble changes in CRP (not AGP), some WHO 
recommendations suggest including both CRP and AGP in analyses of serum 
ferritin if both measures are available (75). Likelihood ratio tests comparing each 
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model reported in this paper with and without AGP as a covariate did not identify 
statistical differences between these models (results not shown). 
 This analysis is subject to several limitations. First, most children in this 
study had high levels of anti-NmA antibody both at 2 and 3.5 years post-
vaccination. It is therefore unclear whether a relationship between serum ferritin 
and MenAfriVac-elicited rSBA antibody is likely to have an immediate impact on 
protection against meningococcal meningitis. Second, our analysis was set up to 
identify associations between iron or vitamin A and antibody at two discrete time 
points post-vaccination. As such, this analysis is not able to determine the 
cumulative effect of long-term iron or vitamin A deficiency on MenAfriVac 
antibody persistence over time, nor is it able to identify pre-vaccination factors 
which could affect the immunogenicity of MenAfriVac. Including additional pre- 
and post-vaccination measurements of MenAfriVac antibody and iron or vitamin 
A in future studies would aid in identifying long-term trends and potential 
relationships between iron or vitamin A and MenAfriVac antibody.  
Finally, this was a secondary analysis intended for hypothesis generation. 
As such, it includes a relatively small number of individuals, and may lack 
statistical power to identify small associations between iron and vitamin A status 
and MenAfriVac-elicited antibody. Results from this analysis should therefore be 
interpreted as suggestions for directing future research. 
Despite these limitations, this exploratory analysis identifies a potential 
relationship between serum ferritin and MenAfriVac antibody persistence that has 
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not been described before in the literature. Results from this analysis add to the 
existing literature on iron status and vaccine response, and suggest future 
studies to identify the potential longitudinal effects of iron status and severe iron 
deficiency on post-vaccination persistence of antibody.  
	
Conclusions 
This analysis identified an association between log ferritin and rSBA at 2 
years post-vaccination. However, this analysis did not identify an association 
between log sTfR or RBP and rSBA at 2 years post-vaccination. This analysis 
also did not identify an association between log ferritin, log sTfR, or RBP and 
change in rSBA from 2 to 3.5 years post-vaccination. To our knowledge, this is 
the first study to investigate possible relationships between iron and vitamin A 
status and antibody persistence from meningococcal polysaccharide-protein 
conjugate vaccine. Future studies should be undertaken to confirm these findings 
in larger cohorts and to identify the potential longitudinal effects of iron status on 
post-vaccination persistence of antibody. 
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Table 6. Descriptive statistics of children originally enrolled in 2012 and the 
subset of the originally enrolled children that were followed to a second visit in 
2014. 
Characteristic Initial visit: 2 years post-
vaccination 
(n = 200) 
Follow-up visit subset: 
3.5 years post-
vaccination 
(n = 165) 
Participant age at cohort visit: 
mean (SD) 
6.0 (1.3) 7.4 (1.3) 
Participant age during vaccination 
campaign: mean (SD) 
4.0 (1.3) 3.9 (1.3) 
Female gender: N (%) 103 (51.5) 86 (52.8) 
MenA rSBA: GMT (95% CI) 2870.9 (2517.2 – 
3274.4) 
1686.1 (1416.0 – 
2007.8) 
MenA IgG ELISA: GMC (95% CI) 3.8 (3.2 – 4.5) 4.9 (4.1 – 5.8) 
Micronutrient status: median 
(IQR) 
  
Ferritin (µg/L) 41.4 (23.9 – 63.5) 51.8 (35.6 – 67.5) 
Soluble transferrin receptor 
(mg/L) 
7.2 (6.1 – 8.7) 6.5 (5.8 – 7.7) 
Retinol binding protein (µmol/L) 0.9 (0.8 – 1.1) 1.0 (0.8 – 1.1) 
Micronutrient status: N (%)   
Low ferritin 26 (13.0) 6 (3.7) 
High sTfR 60 (30.0) 25 (15.3) 
Low RBP 37 (18.5) 37 (22.7) 
Anthropometric measurements   
Height-for-age Z-score (HAZ): 
mean (SD) 
-0.7 (1.2) -0.5 (1.1) 
Weight-for-age Z-score (WAZ): 
mean (SD) 
-0.8 (1.1) -0.8 (1.0) 
Inflammation markers: median 
(IQR) 
  
C-reactive protein (mg/L) 0.4 (0.2 – 1.2) 0.3 (0.1 – 0.7) 
Alpha-1 acid glycoprotein (g/L) 0.8 (0.7 – 1.1) 0.6 (0.5 – 0.8) 
Inflammation marker status: N (%)   
High CRPa 13 (6.5) 7 (4.3) 
High AGP 57 (28.5) 23 (14.2) 
a One individual was missing information for CRP at the follow-up visit. 
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Table 7. Linear regression analyses with proportional increase or decrease in 
antibody titer at 2 years post-vaccination as the outcome.a 
Covariate Fold change 
(adjusted)b 
95% CI 
rSBA    
Log ferritin 0.40 0.20 0.81 
Log sTfR 2.49 0.43 14.32 
RBP 1.12 0.47 2.65 
a Each row in the table represents a separate regression analysis, adjusted for 
participant age at enrollment, sex, CRP, AGP, HAZ and WAZ. 
b Coefficients are interpreted as the fold change in rSBA at 2 years post-
vaccination per unit change in log ferritin, log sTfR, or RBP. 
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Table 8. Linear regression analysis with proportional increase or decrease 
antibody titer difference from the first cohort visit to the second visit as the 
outcome. a  
Covariate Fold change 
(adjusted)b 
95% CI 
rSBA    
Log ferritin 1.63 0.78 3.41 
Log sTfR 0.41 0.07 2.48 
RBP 0.67 0.28 1.61 
a Each row heading in the table represents a separate regression analysis, 
adjusted for participant age at enrollment, sex, CRP, AGP, HAZ and WAZ. 
b Coefficients are interpreted as the fold change in rSBA from 2 to 3.5 years post-
vaccination, per unit change in log ferritin, log sTfR, or RBP. 
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Table 9. Marginal predicted values of rSBA, based on linear regression analyses 
with antibody titer at 2 years post-vaccination as the outcome.a 
Covariate rSBA value 
(adjusted) b 
95% CI 
Ferritin    
1st quintile 3246.32 2524.79 4174.04 
2nd quintile 2633.31 2195.13 3158.97 
3rd quintile 2300.78 1893.40 2795.83 
4th quintile 2014.48 1572.58 2580.54 
sTfR    
1st quintile  2329.06 1837.06 2952.80 
2nd quintile 2427.00 1985.92 2966.06 
3rd quintile 2566.63 2135.99 3084.11 
4th quintile 2705.84 2194.82 3335.83 
RBP    
1st quintile  2585.58 2037.31 3281.39 
2nd quintile 2565.08 2107.08 3122.64 
3rd quintile 2539.24 2106.03 3061.58 
4th quintile 2513.67 1996.85 3164.23 
a Each row heading in the table represents a separate regression analysis, 
adjusted for participant age at enrollment, sex, CRP, AGP, HAZ and WAZ.  
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Table 10. Linear regression analysis with proportional increase or decrease in 
antibody titer at 3.5 years post-vaccination, compared to 2 years post-
vaccination.a 
Covariate Fold change in rSBA 
from 2 to 3.5 years 
post-vaccination 
(adjusted) b 
95% CI 
Ferritin    
1st quintile  0.54 0.40 0.73 
2nd quintile 0.61 0.49 0.76 
3rd quintile 0.66 0.52 0.83 
4th quintile 0.71 0.53 0.95 
sTfR    
1st quintile  0.67 0.51 0.89 
2nd quintile 0.65 0.51 0.82 
3rd quintile 0.61 0.49 0.76 
4th quintile 0.57 0.44 0.74 
RBP    
1st quintile  0.67 0.51 0.89 
2nd quintile 0.64 0.51 0.81 
3rd quintile 0.60 0.48 0.75 
4th quintile 0.56 0.43 0.74 
a Each row heading in the table represents a separate regression analysis, 
adjusted for participant age at enrollment, sex, CRP, AGP, HAZ and WAZ.  
b A fold change of 1 indicates no change in antibody titer; a fold change of 0.5 
indicates a 50% decrease in antibody titer at 3.5 years post-vaccination 
compared to 2 years post-vaccination. 
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Figure 3. Predicted mean values of rSBA according to serum ferritin at 2 years 
post-vaccination. a 
 
  
 
a Upper bound values for the 95% confidence interval are cut off at rSBA = 20000 
for ease of viewing. The maximum value for the upper bound is 27523.1. 
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Figure 4. Predicted mean values of rSBA according to sTfR at 2 years post-
vaccination.  
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Figure 5. Predicted mean values of rSBA according to RBP at 2 years post-
vaccination.  
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Figure 6. Predicted mean values of the fold change in rSBA from 2 to 3.5 years 
post-vaccination, according to serum ferritin at 2 years post-vaccination.  
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Figure 7. Predicted mean values of the fold change in rSBA from 2 to 3.5 years 
post-vaccination, according to sTfR at 2 years post-vaccination.  
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Figure 8. Predicted mean values of the fold change in rSBA from 2 to 3.5 years 
post-vaccination, according to RBP at 2 years post-vaccination.  
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Chapter 3: Iron status and nasopharyngeal carriage of Neisseria 
meningitidis 
 
 
Introduction 
Meningococcal meningitis caused by the bacterium Neisseria meningitidis 
(Nm) has historically been a serious public health problem in the African 
meningitis belt (7, 12). Disease outbreaks due to Nm can be difficult to predict. 
The prevalence of asymptomatic carriage of Nm is recognized as a predictive 
factor in meningococcal meningitis outbreaks (43, 44), but it has been noted that 
relatively little is known about the natural history of nasopharyngeal carriage of 
meningococcal meningitis (45, 46). A better understanding of the risk factors for 
Nm carriage could help contextualize the high variation in carriage prevalence 
and carriage type seen across the meningitis belt (45, 46). 
One potential factor affecting risk of Nm carriage is human iron status. Iron 
is an important component of immune system function and can affect immune 
function by interacting with T-, B-, and NK-cells (37, 82). Iron deficiency and iron 
overload have both been implicated in poor immune function (35, 37). Low iron 
has been associated with reduced cell-mediated immune function (83) and 
reduced cytotoxic activity against pathogens (83, 84), but several studies have 
noted that this latter association may be confounded in observational studies by 
other demographic factors (83), including socio-economic status (85). 
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Conversely, high iron is associated with increased risk of infection (35, 37, 67), 
especially for malaria  (70, 86). The immune response to infection can also affect 
iron levels: during infection, the body sequesters iron in order to avoid the 
inactivation of macrophages and their subsequent immune effector pathways 
(37).  
In addition to existing host interactions between immune function and iron 
metabolism, most pathogens—including Nm—require iron in order to replicate 
and have therefore evolved specialized mechanisms for obtaining iron from 
human hosts (87). Given these iron-immunity and host-pathogen interactions, it 
is therefore possible that individual iron status may be related to the risk for 
successful Nm colonization. We hypothesized that asymptomatic 
nasopharyngeal Nm carriage among children and adults in the African meningitis 
belt would differ based on iron status [measured by serum ferritin and soluble 
transferrin receptor (sTfR)]. We investigated this hypothesis using a matched 
case-control study design applied to a large-scale cohort study on 
meningococcal carriage in the African meningitis belt. 
 
Methods 
Setting and study participants 
 This is a retrospective case-control study nested within a cohort study 
originally conducted by the African Meningococcal Carriage Consortium 
(MenAfriCar Consortium), a partnership between seven African and twelve 
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northern research institutes (37). The primary aim of the Consortium is to 
investigate the epidemiology of nasopharyngeal carriage of Nm in the African 
meningitis belt (88). The methods used by the Consortium to design and 
implement longitudinal cohort studies have been described in detail elsewhere 
(36). This analysis was completed using data collected from MenAfriCar 
Consortium pre-vaccination cross-sectional surveys and household contact 
surveys, conducted in seven countries in the meningitis belt (Chad, Ethiopia, 
Ghana, Mali, Niger, Nigeria, and Senegal) during 2010-2012, according to a 
common protocol (45, 88, 89). In each country, participants were drawn from one 
rural and one urban study site; eligible households in each study area were then 
identified using simple random sampling from a current demographic surveillance 
system or a census conducted specifically for the study. Within households, 
individuals were selected by age-stratified random sampling to be invited to 
participate in the original study (age groups defined as < 1 year, 1-4 years, 5-14 
years, 15-29 years, and ≥ 30 years). Three cross-sectional surveys were then 
conducted at each site using this design: two in rainy seasons and one in a dry 
season. Participants who consented to participate in the study provided 
demographic and household information through a structured questionnaire. 
Study staff collected a nasopharyngeal swab (that touched both the posterior 
pharynx and the tonsils). In addition, study staff randomly selected an age-
stratified random sample of 400 individuals ≥ 6 months of age in each study from 
the larger sample and collected a 5mL blood sample to be tested for the 
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presence of antibody to Nm. For our secondary analysis, these blood samples 
were also tested for nutritional biomarkers including serum ferritin and sTfR. 
 Identification of an individual testing positive for Nm at the initial cross-
sectional visit triggered a second visit to the household, during which all 
household members were invited to participate in a follow-up, longitudinal 
household study. In the longitudinal study, consenting household members 
provided nasopharyngeal swabs twice a month for 2 months and then monthly 
for an additional 4 months, as well as a 5mL blood sample at the first visit (88). In 
these studies, an age-stratified sample size of 800 individuals per research 
center was calculated to be the number of individuals required to allow 
meaningful comparisons across centers (90). These studies were approved by 
the London School of Hygiene and Tropical Medicine Ethics Committee as well 
as the ethics committees of each of the seven African partner institutions, except 
for Chad, which did not have a formal ethical committee. In Chad, approval was 
granted by a special Ministry of Health committee established to oversee the 
studies (88). 
We used a case-control study design to analyze the relationship between 
iron status and risk of Nm carriage in these study participants. We defined cases 
as individuals who participated in either the cross-sectional or the longitudinal 
Nm carriage study visits, whose nasopharyngeal samples tested positive for Nm 
and who provided a blood sample for testing at the time they provided a 
nasopharyngeal sample. Controls were participants in cross-sectional or 
	 53 
longitudinal visits whose nasopharyngeal samples tested negative for Nm and 
who provided a blood sample for testing at the same time they provided a 
nasopharyngeal sample. Cases were matched to up to two controls based on 
age (range: plus or minus 1 year), sex, study site, and date of swab (range: plus 
or minus 30 days). Since baseline iron status (75) and risk of Nm carriage (3) can 
both differ by age, we conducted this analysis stratified by age groups (6 months-
4 years, 5-11 years, 12-17 years, and ≥ 18 years old). 
 
Laboratory methods 
The precise laboratory methods for assessment of Nm carriage (88) and 
nutritional biomarkers (45, 88, 89) have been described in detail elsewhere. 
Briefly, study staff collected pharyngeal swabs from participants and plated the 
swabs directly onto modified Thayer-Martin agar plates in the field. One 
suspected colony with morphology indicative of Neisseria species was cultured 
onto two blood agar plates, which were then incubated at 37° C for 18-24 hours. 
Cultured bacteria were then tested for oxidase activity and Gram stained. 
Bacteria that were oxidase-positive and Gram-negative were tested for g-
glutamyl-transferase activity (GGT), b-galactosidase activity with ortho-
nitrophenyl-b-D-galactopyranoside (ONPG), and butyrate esterase activity 
(Tributyrin). Isolates that were GGT positive, ONPG negative and Tributyrin 
negative were identified as Nm species and serogrouped by slide agglutination. 
To confirm the result of Neisseria spp. identified using culture techniques, the 
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DNA of oxidase-positive, Gram-negative bacteria were amplified and sequenced 
in a hierarchical analysis with a high-throughput Sanger sequencing pipeline 
(88). Blood serum samples were also tested for serum ferritin and sTfR 
(nutritional biomarkers representing iron status), and C-reactive protein (CRP, an 
acute phase protein) using a multiplex sandwich ELISA with HRP-coupled 
antibodies (88). In the absence of infection, ferritin reflects dietary iron status. 
However, serum ferritin is an acute phase protein, meaning its blood 
concentrations increase during acute infection, regardless of dietary iron status. 
Therefore, we used CRP—another acute phase protein—to determine acute 
infection status and aid interpretation of serum ferritin levels. sTfR levels are less 
affected by acute infection (74) and reflect availability of iron in the bone marrow. 
 
Statistical analysis 
We used conditional logistic regression models to assess whether there 
was an association between serum ferritin or sTfR and risk of Nm carriage, using 
continuous log10 ferritin and continuous log10 sTfR as independent variables. We 
log10-transformed ferritin and sTfR for these analyses because the underlying 
distributions of both biomarkers were heavily right-skewed. Since cases and 
controls were matched on age, sex, study site, and date of swab, these 
covariates were not included in any of the adjusted regression models. However, 
we controlled for the number of residents in the household, and ran separate 
regression models excluding individuals likely to have acute infection (CRP > 5 
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mg/L). Additionally, since baseline iron status and risk of carriage can both vary 
by age, we report age-stratified results (children < 5, children 5-11, children 12-
17, and adults ≥ 18 years old). All analyses were performed using Stata 15 
(College Station, TX). 
 
Results 
 We identified 194 cases nested within the larger study who met the 
eligibility criteria and who were matched on age, sex, site, and swab date to 332 
controls also drawn from the larger study (Figure 1). Of the 194 cases, 138 
(71.1%) were matched to two controls; the remaining 56 cases were matched to 
one control. There were 281 (53.4%) female participants; 329 (62.6%) were 
children under the age of 18 (Table 11). The median (IQR) serum ferritin was 
51.2 µg/L (29.5 – 89.4 µg/L); the median (IQR) sTfR was 7.4 (5.8 – 11.8) mg/L 
(Table 11). Participants reported a median number of 6 (IQR: 5 – 9) residents 
living in their household (Table 11).  
 In an unadjusted conditional logistic regression, increasing log serum 
ferritin was significantly related to decreased odds of Nm carriage in children 5-
11 years old (uOR: 0.57, 95% CI: 0.34 – 0.98). After adjusting for the number of 
residents in the household, results were similar (aOR: 0.28, 95% CI: 0.11 – 0.68) 
(Table 12). In a sensitivity analysis excluding individuals with CRP > 5 mg/L, this 
relationship remained (aOR: 0.30, 95% CI: 0.12 – 0.78), though it was 
statistically significant in the adjusted regression model only (Table 12). 
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Conditional logistic regressions did not identify a relationship between log serum 
ferritin and carriage for children less than 5 years old, children 12-17 years old, or 
adults ≥ 18 years old; excluding individuals with CRP > 5 mg/L yielded similar 
results (Table 12). 
 In unadjusted conditional logistic regressions, increasing sTfR was 
significantly related to decreased odds of Nm carriage in children 12-17 years old 
(Table 13); these results were similar including or excluding individuals with CRP 
> 5 mg/L. However, this relationship did not exist in any other age group, and the 
effect did not remain after adjusting for the number of residents in the household 
(Table 13). 
 
Discussion 
 In our analysis, increasing log serum ferritin was significantly related to 
reduced odds of Nm carriage in children 5-11 years old. These results remained 
after excluding individuals with CRP > 5 mg/L (those likely to have acute 
infection); however, similar results were not seen in other age groups. Similarly, 
sTfR was significantly related to reduced odds of Nm carriage in children 12-17 
years old, though these results did not remain after adjusting for the number of 
residents in the household. Though past studies have considered other 
demographic and social characteristics related to the risk of Nm carriage, 
including age and sex (75), household crowding and kitchen location (87), rainy 
vs. dry season (91), risky behaviors such as smoking and kissing (91), and co-
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colonization with other, non-pathogenic Neisseria species (92), relatively few 
studies have investigated individual biological characteristics associated with Nm 
carriage (91). Despite the established relationship between iron and immune 
system function, this study is the first to investigate whether iron biomarkers are 
related to the odds of Nm carriage.  
 Since ferritin is an acute phase iron storage protein, higher levels of ferritin 
can either indicate higher dietary iron or a higher degree of iron sequestration 
during acute infection (35). Our analysis finds similar results when individuals 
with CRP > 5 mg/L are excluded, so it is likely that higher ferritin in this group of 
individuals is indicative of dietary iron status rather than a result of acute 
infection. Additionally, our analysis identified a statistically significant relationship 
between increasing sTfR and reduced odds of Nm carriage among 12-17 year-
olds; since sTfR is less apt to change during acute infection, it is likely that our 
findings reflect the relationship between dietary iron and Nm carriage risk. 
This analysis has three main limitations. First, although this analysis 
utilized all available cases from a larger carriage study, and the majority of cases 
were matched to two controls, there still remained a moderately high level of 
variability in estimates obtained from conditional logistic regression models. 
Since point estimates with and without adjustment were similar, and point 
estimates including and excluding individuals with high CRP are similar, it is 
plausible that a larger sample size would reveal similar point estimates with 
smaller 95% confidence intervals. However, given the information currently 
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available from this analysis, we cannot conclude whether this relationship would 
be consistent given a larger sample size.  
Second, information about iron status was only collected at one time point 
during carriage (at one time point only for controls), and this analysis identified 
carriage status at only one time point. Therefore, our analysis cannot identify 
whether high iron occurs before or after nasopharyngeal Nm colonization. 
However, it is unlikely that nasopharyngeal carriage would effect subsequent 
changes iron status through inflammation, as it has been noted that 
nasopharyngeal carriage does not activate an acute inflammatory immune 
response (93).  
Finally, this analysis measured iron using serum ferritin and sTfR as 
biomarkers. However, there are many other biomarkers of iron that are capable 
of describing different aspects of iron’s role in immune function and acute 
inflammation. For example, it is known that Nm uses human lactoferrin for its iron 
needs (94), and that lactoferrin is more highly active at mucosal surfaces (as 
compared to serum ferritin and sTfR, which are systemically active) (95). 
Incorporating information from these additional iron biomarkers in future analyses 
may therefore provide a more complete picture of the potential relationship 
between iron and asymptomatic Nm carriage.  
 
Conclusions 
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 Our analysis identified a relationship between increasing log serum ferritin 
and reduced odds of Nm carriage in children 5-11 years old, and increasing sTfR 
and reduced odds of Nm carriage in children 12-17 years old. These 
relationships remained after excluding individuals with CRP > 5 mg/L, but were 
not seen in other age groups. Future studies should focus on high-risk 
populations for carriage, including children, and consider other iron biomarkers 
which may interact directly with Nm, including lactoferrin. 
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Table 11. Descriptive and anthropometric characteristics of study participants. 
Characteristics Controls 
N = 332 
Cases 
N = 194 
Female sex: N (%) 178 (53.6) 103 (53.1) 
Country: N (%)   
Mali 32 (9.6) 17 (8.8) 
Niger 221 (66.6) 131 (67.5) 
Ghana 2 (0.6) 2 (1.0) 
Nigeria 1 (0.3) 1 (0.5) 
Senegal 16 (4.8) 11 (5.7) 
Ethiopia 60 (18.1) 32 (16.5) 
Meningitis vaccination   
No 227 (68.4) 131 (67.5) 
In past year 83 (25.0) 49 (25.3) 
In past 3 years 22 (6.6) 12 (6.2) 
Don’t know 0 (0) 2 (1.0) 
Age group   
6 months-5 years 33 (9.9) 18 (9.3) 
5-11 years 95 (28.6) 54 (27.8) 
12-17 years 81 (24.4) 48 (24.7) 
≥ 18 years 123 (37.1) 74 (38.1) 
Number of residents in the 
household 
6 (4 – 9) 6 (5 – 9) 
Iron biomarkers: median (IQR)   
Serum ferritin (µg/L) 52.7 (31.7 – 94.6) 47.8 (25.7 – 80.8) 
sTfR (mg/L) 7.3 (5.8 – 11.6) 7.4 (5.8 – 12.3) 
Inflammatory marker: median (IQR)   
CRP (mg/L) 0.8 (0.3 – 2.9) 0.8 (0.3 – 2.2) 
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Table 12. Conditional logistic regressions describing the odds of carriage 
according to log serum ferritin, by age group and CRP levels.a 
Characteristic uOR 95% CI aORb 95% CI 
Age-stratified models: all 
individuals 
    
Children < 5 years 1.24 0.55 – 2.80 1.33 0.54 – 3.26 
Children 5-11 years 0.57 0.34 – 0.98 0.28 0.11 – 0.68 
Children 12-17 years 0.77 0.47 – 1.28 0.73 0.43 – 1.25 
Adults ≥ 18 years 0.78 0.50 – 1.20 0.87 0.54 – 1.41 
     
Age-stratified models: 
including only individuals 
with CRP < 5 mg/L 
    
Children < 5 years 0.92 0.26 – 3.27 1.20 0.26 – 5.48 
Children 5-11 years 0.60 0.31 – 1.15 0.30 0.12 – 0.78 
Children 12-17 years 0.77 0.43 – 1.39 0.70 0.37 – 1.33 
Adults ≥ 18 years 0.91 0.55 – 1.51 0.97 0.56 – 1.67 
a Each row represents results from one conditional logistic regression, where 
cases and controls were matched on age, sex, study site, and date of swab. 
b Adjusted models control for number of residents in the household. 
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Table 13. Conditional logistic regressions describing the odds of carriage 
according to log soluble transferrin receptor, by age group and CRP levels. a 
Characteristic uOR 95% CI aORb 95% CI 
Age-stratified models: all 
individuals 
    
Children < 5 0.76 0.21 – 2.74 0.74 0.19 – 2.88 
Children 5-11 years 1.10 0.49 – 2.44 1.62 0.58 – 4.53 
Children 12-17 years 0.34 0.12 – 0.98 0.42 0.15 – 1.24 
Adults ≥ 18 1.25 0.58 – 2.71 0.96 0.42 – 2.21 
     
Age-stratified models: 
including only individuals 
with CRP < 5 mg/L 
    
Children < 5 0.81 0.15 – 4.30 0.74 0.11, 5.20 
Children 5-11 years 1.11 0.43 – 2.89 2.01 0.62 – 6.62 
Children 12-17 years 0.31 0.10 – 0.96 0.36 0.11 – 1.15 
Adults ≥ 18 1.96 0.76 – 5.09 1.53 0.56, 4.12 
a Each row represents results from one conditional logistic regression, where 
cases and controls were matched on age, sex, study site, and date of swab. 
b Adjusted models control for number of residents in the household. 
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Conclusions 
	
 
Main findings 
This dissertation investigated three potential relationships between 
nutrition and immune function in the context of meningococcal disease and 
vaccine response in the African meningitis belt. In children 5 years old and 
younger, anthropometric Z-scores for height-for-age (HAZ), weight-for-height 
(WHZ), and weight-for-age (WAZ) were not significantly associated with pre-
vaccination antibody titers; nor were they related to the change in antibody from 
pre-vaccination to 28-35 days post vaccination with either a polysaccharide or a 
polysaccharide-protein conjugate vaccine. Although there was a significant 
decline in vaccine-elicited antibody over time during the year post-vaccination, 
HAZ and WHZ were not found to be related to this decline. However, higher WAZ 
was significantly associated with an increase in antibody elicited by 
polysaccharide vaccine in the year post-vaccination.  
In a different group of children 9 years old and younger, increasing serum 
ferritin was associated with a decrease in antibody elicited by polysaccharide-
protein conjugate vaccine at both 2 and 3.5 years post-vaccination (though this 
relationship was only statistically significant at 2 years post-vaccination). 
However, soluble transferrin receptor (sTfR) and retinol binding protein (RBP) 
were both unrelated to levels of vaccine-elicited antibody at 2 and 3.5 years post-
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vaccination. Neither serum ferritin, sTfR, nor RBP were related to the fold change 
in vaccine-elicited antibody from 2 to 3.5 years post-vaccination.  
Finally, in a third population of children and adults, both increasing serum 
ferritin and increasing sTfR were related to reduced odds of asymptomatic 
nasopharyngeal carriage of Neisseria meningitidis. Although these results were 
only seen for specific age groups, the findings remained after excluding 
individuals with likely concurrent acute infection. 
 
Strengths and limitations 
 Each analysis in this dissertation makes novel use of existing data to 
answer questions regarding nutrition and immune function that are directly 
applicable to individuals living in the African meningitis belt. Since PEU, iron 
deficiency, and vitamin A deficiency are relatively common in the African 
meningitis belt, identifying the relationships between immune function and 
nutrition in this area can provide additional insight into the risks surrounding 
meningococcal disease. Although many studies have already noted relationships 
between undernutrition and other infectious diseases including respiratory 
diseases and diarrhea (29, 63), measles (96), poliovirus (27), and malaria (70, 
86), no study has yet assessed the relationship between nutrition and immune 
function in the context of meningococcal disease. 
Each analysis in this dissertation is a secondary analysis of data originally 
collected for a different purpose. As such, these analyses are subject to the 
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dangers of secondary data use, including potential unmeasured confounding and 
study design limitations. Additionally, these studies did not seek specifically to 
enroll individuals with PEU or deficiency in iron or vitamin A, and in some cases 
may have directly excluded individuals with severe nutritional deficits. As a result, 
although the results from these studies are likely to be more broadly 
generalizable to individuals living in the African meningitis belt, they may not 
identify relationships between nutrition and immune function seen in individuals 
with severe nutritional deficits. 
   
Implications 
 Existing research on the immunogenicity, efficacy, and effectiveness of 
meningococcal vaccines in areas with high levels of undernutrition can benefit 
from the results of this dissertation. A confirmation that PEU is not related to 
vaccine immunogenicity and is not consistently related to the decline in vaccine-
elicited antibody over a year post-vaccination means that meningococcal 
vaccines can be used to help disrupt the “vicious cycle” of infection and 
malnutrition, as it is an intervention that is effective in children regardless of 
protein-energy nutritional status. It is additionally reassuring that these analyses 
found no relationship between RBP and meningococcal vaccine-elicited 
antibody, since vitamin A deficiency has long been implicated in poor immune 
function and is considered to be a major component of the “vicious cycle” of 
infection and malnutrition (97). 
	 66 
 However, the findings that increasing serum ferritin in children may be 
related to reduced long-term persistence of vaccine-elicited antibody, as well as 
reduced odds of Neisseria meningitidis carriage, warrant further research on this 
topic. Taken together, these findings suggest a potential scenario in which 
children with higher serum ferritin are less likely to be exposed to Nm carriage, 
and may therefore lose a potential prime-boost effect in antibody after 
vaccination, thus comparatively reducing the level of vaccine-elicited antibody at 
longer time periods post-vaccination. However, since neither of the original 
studies that supported these analyses were designed to answer this question, 
and others have noted the potential for unmeasured confounding in studies on 
iron and immune function (83, 85). such a conclusion cannot be made from these 
findings alone. Further research is needed to identify potential direct relationships 
between serum ferritin and immune function in the context of meningococcal 
disease.  
  
Future research 
 This dissertation represents the first time that iron status and 
meningococcal disease have been studied with an epidemiological approach. As 
mentioned above, further research is needed to identify potential direct 
relationships between serum ferritin and immune function in the context of the 
immune response to meningococcal vaccination and meningococcal disease. 
The analyses in this dissertation that identified a link between iron status and 
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immune response to meningococcal disease and meningococcal vaccines were 
not originally designed to answer this question, and as such cannot identify any 
potential direction of causality. These studies cannot identify whether pre-
vaccination iron status is related to long-term antibody persistence, or whether 
iron status over time is related to long-term antibody persistence Similarly, these 
studies cannot identify whether high iron effects change the odds of Nm carriage, 
or whether Nm carriage affects iron status. In order to elucidate these findings, 
longitudinal study designs are required, which would assess iron status and 
either Nm carriage or vaccine-elicited antibody at several time points pre- and 
post-vaccination. Additionally, as previously mentioned, there exist several 
different biomarkers of iron status, each of which could have a unique 
relationship with the immune response to meningococcal vaccination or Nm 
carriage. For example, Nm is known to scavenge iron from human lactoferrin in 
the nasopharynx, and it is believed that lactoferrin is the primary iron source for 
Nm (94). Therefore, future studies should consider additional biomarkers of iron, 
including specifically lactoferrin, to identify potential direct relationships between 
iron status and the immune response to meningococcal vaccination and 
meningococcal disease. 
 
Summary and contribution 
 These analyses do not find consistent evidence of a relationship between 
PEU and meningococcal vaccine immunogenicity, and find no evidence of a 
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relationship between RBP and vaccine-elicited antibody persistence. However, 
the findings of these analyses identify a potential relationship between iron status 
and vaccine-elicited antibody persistence as well as the odds of Nm carriage. 
These findings contribute to the robust existing literature surrounding immune 
response to meningococcal vaccination and factors associated with 
meningococcal disease. They also complement the robust literature investigating 
potential relationships between undernutrition and infectious disease risk and 
vaccine immunogenicity.   
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